Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 82-90

  Kim, Moon Doo ^a   Eun, Su Yong ^a   Jo, Su Hyun ^a  

^a Jeju National University School of Medicine   (South Korea)

Author keywords

Antiemetic drug; Arrhythmias; HERG channel; IKr; Long QT syndrome; Prochlorperazine

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROCHLORPERAZINE;

AMPLITUDE MODULATION; ANIMAL CELL; ARRHYTHMOGENESIS; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG ACTIVITY; DRUG EFFECT; DRUG USE; ELECTRIC POTENTIAL; FEMALE; FREQUENCY ANALYSIS; GUINEA PIG; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART VENTRICLE; IC 50; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TEMPERATURE; XENOPUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; ARRHYTHMIAS, CARDIAC; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; MYOCYTES, CARDIAC; OOCYTES; POTASSIUM; PROCHLORPERAZINE; TIME FACTORS; XENOPUS;

EID: 33746657141     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.009     Document Type: Article

References (39)

1. Abott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K.W., Keating M.T., and Goldstein S.A. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 (1999) 175-187
2. Arita M., and Surawicz B. Electrophysiologic effects of phenothiazines on canine cardiac fibers. J. Pharmacol. Exp. Ther. 184 (1973) 619-630
3. Balsessarini R.J., and Tarazi F.I. Drugs and the treatment of psychiatric disorders. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics (2001), McGraw-Hill, NY 485-520
4. Barry D.M., Xu H., Schuessler R.B., and Nerbonne J.M. Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit. Circ. Res. 83 (1998) 560-567
5. Baselt R.C., and Cravey R.H. Disposition of Toxic Drugs and Chemicals in Man. third ed (1989), Year Book Medical Publishers, Chicago
6. Brown A.M., and Rampe D. Drug-induced long QT syndrome: is HERG the root of all evil?. Pharm. News 7 (2000) 15-20
7. Buckley N.A., and Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 23 (2000) 215-228
8. Buckley N.A., Whyte I.M., and Dawson A.H. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J. Toxicol. Clin. Toxicol. 33 (1995) 199-204
9. + channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. J. Pharmacol. Exp. Ther. 313 (2005) 888-895
10. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
11. Elkayam U., and Frishman W. Cardiovascular effects of phenothiazines. Am. Heart J. 100 (1980) 397-401
12. Fowler A., Taylor W., and Bateman D.N. Plasma prochlorperazine assay by high-performance liquid chromatography-electrochemistry. J. Chromatogr. 380 (1986) 202-205
13. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., and Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res. 47 (2000) 219-233
14. Heath B.M., and Terrar D.A. Separation of the components of the delayed rectifier potassium current using selective blockers of IKr and IKs in guinea-pig isolated ventricular myocytes. Exp. Physiol. 81 (1996) 587-603
15. Hollister L.E., and Kosek J.C. Sudden death during treatment with phenothiazine derivatives. JAMA 192 (1965) 1035-1038
16. Hondeghem L.M., and Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 81 (1990) 686-690
17. Isah A.O., Rawlins M.D., and Bateman D.N. Clinical pharmacology of prochlorperazine in healthy young males. Br. J. Clin. Pharmacol. 32 (1991) 677-684
18. Jeron A., Mitchell G.F., Zhou J., Murata M., London B., Buckett P., Wiviott S.D., and Koren G. Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype. Am. J. Physiol., Heart Circ. Physiol. 278 (2000) H1891-H1898
19. Kiehn J., Lacerda A.E., Wible B., and Brown A.M. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 94 (1996) 2572-2579
20. Kiehn J., Thomas D., Karle C.A., Schols W., and Kubler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedebergs Arch. Pharmacol. 359 (1999) 212-219
21. Lapierre J., Amin M., and Hattangadi S. Prochlorperazine-a review of the literature since 1956. Can. Psychiatr. Assoc. J. 14 (1969) 267-274
22. Lathers C.M., and Lipka L.J. Cardiac arrhythmia, sudden death, and psychoactive agents. J. Clin. Pharmacol. 27 (1987) 1-14
23. Leestma J.E., and Koenig K.L. Sudden death and phenothiazines. Arch. Gen. Psychiatry 18 (1968) 137-148
24. Mitcheson J.S., Chen J., and Sanguinetti M.C. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115 (2000) 229-240
25. Muirhead G.J., Wulff M.B., Fielding A., Kleinermans D., and Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol. 50 (2000) 99-107
26. Pasricha P.J. Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics (2001), McGraw-Hill, NY 1021-1036
27. Pruitt R.D. On sudden death. Am. Heart J. 68 (1964) 111-118
28. Rampe D., Roy M.L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417 (1997) 28-32
29. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58 (2003) 32-45
30. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96 (1990) 195-215
31. Sanguinetti M.C., Jiang C., Curran M.E., and Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81 (1995) 299-307
32. Sankey M.G., Holt J.E., and Kaye C.M. A simple and sensitive H.P.L.C. method for the assay of prochlorperazine in plasma. Br. J. Clin. Pharmacol. 13 (1982) 578-580
33. Shivkumar K. Images in cardiovascular medicine. Labile repolarization from "cell to bedside". Circulation 102 (2000) 817-818
34. Suessbrich H., Waldegger S., Lang F., and Busch A.E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385 (1996) 77-80
35. Taglialatela M., Castaldo P., Pannaccione A., Giorgio G., and Annunziato L. Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. Biochem. Pharmacol. 55 (1998) 1741-1746
36. Tan H.L., Hou C.J., Lauer M.R., and Sung R.J. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann. Intern. Med. 122 (1995) 701-714
37. Thomas D., Wendt-Nordahl G., Rockl K., Ficker E., Brown A.M., and Kiehn J. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J. Pharmacol. Exp. Ther. 297 (2001) 753-761
38. Webster R., Leishman D., and Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Dev. 5 (2002) 116-126
39. Weerapura M., Nattel S., Chartier D., Caballero R., and Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. J. Physiol. 540 (2002) 15-27